News

   

Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business

First preliminary efficacy data from the clinical trial with…

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

• Phase II study in non-small-cell-lung-cancer (NSCLC) to be…

Novo Holdings invests in MATR Foods’ expansion within plant-based fungi food

COPENHAGEN, DENMARK – Today, Novo Holdings announced an initial…

Tom Tacon appointed Business Unit Director of Bionical Virtual Engagement

Willington, UK, June 27, 2024 – Bionical Solutions, a leading…

Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001

EMERALD Study will investigate safety and efficacy of engineered…

Novo Holdings and DLG Group join forces to advance sustainable crop production

Novo Holdings and DLG Group today announced a strategic partnership…

AMSilk to showcase its biofabricated yarns at Première Vision Paris

Neuried, Germany, 25 June 2024: AMSilk GmbH (“AMSilk”), a…

iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials

• Led by new investor Syncona, with participation from the…

Gareth Williams appointed CEO of Bionical Health

Willington, UK, June 19, 2024 – Bionical Solutions, a leading…

Calliditas provides setanaxib patent update

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.